Cargando…

Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients

BACKGROUND: The growing awareness of cardiovascular toxicity from cancer therapies has led to the emerging field of cardio‐oncology, which centers on preventing, detecting, and treating patients with cardiac dysfunction before, during, or after cancer treatment. Early detection and prevention of can...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yadi, Hou, Yuan, Hussain, Muzna, Brown, Sherry‐Ann, Budd, Thomas, Tang, W. H. Wilson, Abraham, Jame, Xu, Bo, Shah, Chirag, Moudgil, Rohit, Popovic, Zoran, Cho, Leslie, Kanj, Mohamed, Watson, Chris, Griffin, Brian, Chung, Mina K., Kapadia, Samir, Svensson, Lars, Collier, Patrick, Cheng, Feixiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763760/
https://www.ncbi.nlm.nih.gov/pubmed/33241727
http://dx.doi.org/10.1161/JAHA.120.019628
_version_ 1783628094839455744
author Zhou, Yadi
Hou, Yuan
Hussain, Muzna
Brown, Sherry‐Ann
Budd, Thomas
Tang, W. H. Wilson
Abraham, Jame
Xu, Bo
Shah, Chirag
Moudgil, Rohit
Popovic, Zoran
Cho, Leslie
Kanj, Mohamed
Watson, Chris
Griffin, Brian
Chung, Mina K.
Kapadia, Samir
Svensson, Lars
Collier, Patrick
Cheng, Feixiong
author_facet Zhou, Yadi
Hou, Yuan
Hussain, Muzna
Brown, Sherry‐Ann
Budd, Thomas
Tang, W. H. Wilson
Abraham, Jame
Xu, Bo
Shah, Chirag
Moudgil, Rohit
Popovic, Zoran
Cho, Leslie
Kanj, Mohamed
Watson, Chris
Griffin, Brian
Chung, Mina K.
Kapadia, Samir
Svensson, Lars
Collier, Patrick
Cheng, Feixiong
author_sort Zhou, Yadi
collection PubMed
description BACKGROUND: The growing awareness of cardiovascular toxicity from cancer therapies has led to the emerging field of cardio‐oncology, which centers on preventing, detecting, and treating patients with cardiac dysfunction before, during, or after cancer treatment. Early detection and prevention of cancer therapy–related cardiac dysfunction (CTRCD) play important roles in precision cardio‐oncology. METHODS AND RESULTS: This retrospective study included 4309 cancer patients between 1997 and 2018 whose laboratory tests and cardiovascular echocardiographic variables were collected from the Cleveland Clinic institutional electronic medical record database (Epic Systems). Among these patients, 1560 (36%) were diagnosed with at least 1 type of CTRCD, and 838 (19%) developed CTRCD after cancer therapy (de novo). We posited that machine learning algorithms can be implemented to predict CTRCDs in cancer patients according to clinically relevant variables. Classification models were trained and evaluated for 6 types of cardiovascular outcomes, including coronary artery disease (area under the receiver operating characteristic curve [AUROC], 0.821; 95% CI, 0.815–0.826), atrial fibrillation (AUROC, 0.787; 95% CI, 0.782–0.792), heart failure (AUROC, 0.882; 95% CI, 0.878–0.887), stroke (AUROC, 0.660; 95% CI, 0.650–0.670), myocardial infarction (AUROC, 0.807; 95% CI, 0.799–0.816), and de novo CTRCD (AUROC, 0.802; 95% CI, 0.797–0.807). Model generalizability was further confirmed using time‐split data. Model inspection revealed several clinically relevant variables significantly associated with CTRCDs, including age, hypertension, glucose levels, left ventricular ejection fraction, creatinine, and aspartate aminotransferase levels. CONCLUSIONS: This study suggests that machine learning approaches offer powerful tools for cardiac risk stratification in oncology patients by utilizing large‐scale, longitudinal patient data from healthcare systems.
format Online
Article
Text
id pubmed-7763760
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77637602020-12-28 Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients Zhou, Yadi Hou, Yuan Hussain, Muzna Brown, Sherry‐Ann Budd, Thomas Tang, W. H. Wilson Abraham, Jame Xu, Bo Shah, Chirag Moudgil, Rohit Popovic, Zoran Cho, Leslie Kanj, Mohamed Watson, Chris Griffin, Brian Chung, Mina K. Kapadia, Samir Svensson, Lars Collier, Patrick Cheng, Feixiong J Am Heart Assoc Original Research BACKGROUND: The growing awareness of cardiovascular toxicity from cancer therapies has led to the emerging field of cardio‐oncology, which centers on preventing, detecting, and treating patients with cardiac dysfunction before, during, or after cancer treatment. Early detection and prevention of cancer therapy–related cardiac dysfunction (CTRCD) play important roles in precision cardio‐oncology. METHODS AND RESULTS: This retrospective study included 4309 cancer patients between 1997 and 2018 whose laboratory tests and cardiovascular echocardiographic variables were collected from the Cleveland Clinic institutional electronic medical record database (Epic Systems). Among these patients, 1560 (36%) were diagnosed with at least 1 type of CTRCD, and 838 (19%) developed CTRCD after cancer therapy (de novo). We posited that machine learning algorithms can be implemented to predict CTRCDs in cancer patients according to clinically relevant variables. Classification models were trained and evaluated for 6 types of cardiovascular outcomes, including coronary artery disease (area under the receiver operating characteristic curve [AUROC], 0.821; 95% CI, 0.815–0.826), atrial fibrillation (AUROC, 0.787; 95% CI, 0.782–0.792), heart failure (AUROC, 0.882; 95% CI, 0.878–0.887), stroke (AUROC, 0.660; 95% CI, 0.650–0.670), myocardial infarction (AUROC, 0.807; 95% CI, 0.799–0.816), and de novo CTRCD (AUROC, 0.802; 95% CI, 0.797–0.807). Model generalizability was further confirmed using time‐split data. Model inspection revealed several clinically relevant variables significantly associated with CTRCDs, including age, hypertension, glucose levels, left ventricular ejection fraction, creatinine, and aspartate aminotransferase levels. CONCLUSIONS: This study suggests that machine learning approaches offer powerful tools for cardiac risk stratification in oncology patients by utilizing large‐scale, longitudinal patient data from healthcare systems. John Wiley and Sons Inc. 2020-11-26 /pmc/articles/PMC7763760/ /pubmed/33241727 http://dx.doi.org/10.1161/JAHA.120.019628 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Zhou, Yadi
Hou, Yuan
Hussain, Muzna
Brown, Sherry‐Ann
Budd, Thomas
Tang, W. H. Wilson
Abraham, Jame
Xu, Bo
Shah, Chirag
Moudgil, Rohit
Popovic, Zoran
Cho, Leslie
Kanj, Mohamed
Watson, Chris
Griffin, Brian
Chung, Mina K.
Kapadia, Samir
Svensson, Lars
Collier, Patrick
Cheng, Feixiong
Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients
title Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients
title_full Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients
title_fullStr Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients
title_full_unstemmed Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients
title_short Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients
title_sort machine learning–based risk assessment for cancer therapy–related cardiac dysfunction in 4300 longitudinal oncology patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763760/
https://www.ncbi.nlm.nih.gov/pubmed/33241727
http://dx.doi.org/10.1161/JAHA.120.019628
work_keys_str_mv AT zhouyadi machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT houyuan machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT hussainmuzna machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT brownsherryann machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT buddthomas machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT tangwhwilson machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT abrahamjame machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT xubo machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT shahchirag machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT moudgilrohit machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT popoviczoran machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT choleslie machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT kanjmohamed machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT watsonchris machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT griffinbrian machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT chungminak machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT kapadiasamir machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT svenssonlars machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT collierpatrick machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients
AT chengfeixiong machinelearningbasedriskassessmentforcancertherapyrelatedcardiacdysfunctionin4300longitudinaloncologypatients